Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Nature Biotechnology
|
August 19, 2003
Engineering of a macromolecular scaffold to develop specific protease inhibitors
A Allart Stoop, Charles S Craik
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 11, 2014
Reply: To PMID 23784528
Emily M Schmidt, Marc Feldmann, A Allart Stoop
Biological Chemistry
|
February 26, 2010
Analysis of an engineered plasma kallikrein inhibitor and its effect on contact activation
A Allart Stoop, Ravi V Joshi, Christopher T Eggers, et al.
European Journal of Immunology
|
July 24, 2015
Tumour necrosis factor receptor I blockade shows that TNF-dependent and TNF-independent mechanisms synergise in TNF receptor associated periodic syndrome
Lucy C Fairclough, A Allart Stoop, Ola H Negm, et al.
Cellular Signalling
|
January 1, 2014
TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-κB pathways and signals TRAF2 protein degradation in macrophages
Gerhard Ruspi, Emily M Schmidt, Fiona McCann, et al.
Arthritis and Rheumatism
|
June 21, 2013
Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures
Emily M Schmidt, Marie Davies, Prafull Mistry, et al.
Plos One
|
September 10, 2015
Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension
Laura J Goodall, Milan Ovecka, Daniel Rycroft, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
June 27, 2014
Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis
Fiona E McCann, Dany P Perocheau, Gerhard Ruspi, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Nature Biotechnology
|
August 19, 2003
Engineering of a macromolecular scaffold to develop specific protease inhibitors
A Allart Stoop, Charles S Craik
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 11, 2014
Reply: To PMID 23784528
Emily M Schmidt, Marc Feldmann, A Allart Stoop
Biological Chemistry
|
February 26, 2010
Analysis of an engineered plasma kallikrein inhibitor and its effect on contact activation
A Allart Stoop, Ravi V Joshi, Christopher T Eggers, et al.
European Journal of Immunology
|
July 24, 2015
Tumour necrosis factor receptor I blockade shows that TNF-dependent and TNF-independent mechanisms synergise in TNF receptor associated periodic syndrome
Lucy C Fairclough, A Allart Stoop, Ola H Negm, et al.
Cellular Signalling
|
January 1, 2014
TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-κB pathways and signals TRAF2 protein degradation in macrophages
Gerhard Ruspi, Emily M Schmidt, Fiona McCann, et al.
Arthritis and Rheumatism
|
June 21, 2013
Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures
Emily M Schmidt, Marie Davies, Prafull Mistry, et al.
Plos One
|
September 10, 2015
Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension
Laura J Goodall, Milan Ovecka, Daniel Rycroft, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
June 27, 2014
Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis
Fiona E McCann, Dany P Perocheau, Gerhard Ruspi, et al.
Page
of 1